Sirtex Announces New U.S. Medical Oncology Consultant.WILMINGTON, Mass. -- Sirtex, a leading developer of targeted and innovative cancer therapies, is pleased to announce Dean H. Gesme, Jr., M.D., F.A.C.P., F.A.C.P.E., has been appointed as a medical oncology consultant. Dr. Gesme brings more than 20 years of oncology experience to Sirtex and its network of treating physicians across the United States. Sirtex manufactures SIR-Spheres[R] microspheres, the only FDA-approved microsphere therapy for colorectal cancer that metastasizes to the liver.1 Sirtex's U.S. headquarters are located in Wilmington, Mass. Dr. Gesme currently practices medicine at Minnesota Hematology-Oncology in Minneapolis, Minn. He attended medical school at the University of Iowa Not to be confused with Iowa State University. The first faculty offered instruction at the University in March 1855 to students in the Old Mechanics Building, situated where Seashore Hall is now. In September 1855, the student body numbered 124, of which, 41 were women. College of Medicine, and completed his residency in internal medicine at the U.S. Public Health Service Hospital in San Francisco, Calif., where he served as a Commissioned Officer. He was a fellow in medical oncology at the University of Minnesota (body, education) University of Minnesota - The home of Gopher. http://umn.edu/. Address: Minneapolis, Minnesota, USA. in Minneapolis, Minn. where he also served as a postdoctoral associate. Dr. Gesme is board certified in medical oncology, internal medicine and medical management. "We are excited to have Dr. Gesme join our growing group of medical experts at Sirtex," says Nat Geissel, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Sirtex Medical Inc. "His experience as an oncologist, in addition to his research and involvement with prestigious oncology organizations, will be pivotal as we expand the use of microsphere therapy for advanced liver tumors and work to further integrate SIR-Spheres microspheres with other oncology therapies." Dr. Gesme is a fellow with the American College of Physicians The American College of Physicians (ACP) is a national organization of doctors of internal medicine (internists), physicians who specialize in the prevention, detection and treatment of illnesses in adults. and American College of Physician Executives. He is also a member of the American Medical Association American Medical Association (AMA), professional physicians' organization (founded 1847). Its goals are to protect the interests of American physicians, advance public health, and support the growth of medical science. , American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. , American Society of Hematology and American College of Physicians. He currently serves on the Ad Hoc Committee ad hoc committee A committee formed with the purpose of addressing a specific issue or issues, which theoretically is disbanded once its raison d'etre is finished on Workforce for the American Society of Clinical Oncology, and the editorial board of the Journal of Oncology Practice. In the past, Dr. Gesme served as the Chair, By-Laws Committee, and the Chair, Clinical Practice Committee of the American Society of Clinical Oncology (ASCO). He also served as the Chair, Patient Advocacy Committee, and Co-Chair, Program Committee, of the Association of Community Cancer Centers (ACCC). From 2001-2004, he served on the editorial board for C.U.R.E. Cancer Updates, Research and Education magazine. 1 Sirtex Medical Inc.'s SIR-Spheres[R] microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR FUDR, FUdR floxuridine. FUDR see floxuridine. chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer-reviewed literature is different from the approved USA labeling for SIR-Spheres. About Selective Internal Radiation Therapy internal radiation therapy Brachytherapy, see there (SIRT) using SIR-Spheres microspheres Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone. SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America UNITED STATES OF AMERICA. The name of this country. The United States, now thirty-one in number, are Alabama, Arkansas, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel and India. SIRT is available in 140 treatment centers around the world, and more than 6500 patients have been treated to date. Approximately 90 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 86 medical centers. For more information, visit www.sirtex.com. [R] SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion